Loading...
No new antiretrovirals have been approved by the FDA since January 2008, but data from CROI this year suggest that the drug development process is alive and well for some agents, including the recently named integrase inhibitor dolutegravir (formerly GSK-572), the first-in-class attachment inhibitor BMS-663068, and the tenofovir prodrug GS-7340. Promising phase II results were presented for all three drugs.
Dolutegravir has previously demonstrated excellent virologic activity in both treatment-naive and treatment-experienced patients in phase IIb studies (Abstracts MOAB0105 and THLBB205, AIDS 2010). In the manufacturer-supported VIKING study, Joseph Eron and colleagues reported the 10-day antiviral activity of functional monother…